Annexin Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Annexin Pharmaceuticals's earnings have been declining at an average annual rate of -8.6%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually.
Key information
-8.6%
Earnings growth rate
40.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | n/a |
| Return on equity | -731.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Annexin Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -46 | 9 | 38 |
| 31 Dec 23 | 0 | -44 | 8 | 36 |
| 30 Sep 23 | 0 | -40 | 13 | 26 |
| 30 Jun 23 | 0 | -38 | 12 | 26 |
| 31 Mar 23 | 0 | -41 | 11 | 30 |
| 31 Dec 22 | 0 | -41 | 12 | 28 |
| 30 Sep 22 | 0 | -47 | 8 | 37 |
| 30 Jun 22 | 0 | -45 | 9 | 35 |
| 31 Mar 22 | 0 | -43 | 11 | 32 |
| 31 Dec 21 | 0 | -52 | 11 | 42 |
| 30 Sep 21 | 0 | -53 | 10 | 45 |
| 30 Jun 21 | 0 | -53 | 11 | 44 |
| 31 Mar 21 | 0 | -55 | 11 | 46 |
| 31 Dec 20 | 0 | -44 | 11 | 34 |
| 30 Sep 20 | 0 | -38 | 10 | 28 |
| 30 Jun 20 | 0 | -36 | 10 | 27 |
| 31 Mar 20 | 0 | -31 | 8 | 23 |
| 31 Dec 19 | 0 | -28 | 8 | 21 |
| 30 Sep 19 | 0 | -25 | 8 | 17 |
| 30 Jun 19 | 0 | -24 | 7 | 16 |
| 31 Mar 19 | 0 | -25 | 8 | 17 |
| 31 Dec 18 | 0 | -29 | 8 | 20 |
| 30 Sep 18 | 0 | -31 | 8 | 23 |
| 30 Jun 18 | 0 | -30 | 8 | 22 |
| 31 Mar 18 | 0 | -32 | 8 | 25 |
| 31 Dec 17 | 0 | -31 | 7 | 24 |
| 30 Sep 17 | 0 | -25 | 6 | 20 |
| 30 Jun 17 | 0 | -26 | 4 | 22 |
| 31 Mar 17 | 0 | -17 | 3 | 15 |
| 31 Dec 16 | 0 | -10 | 1 | 9 |
| 31 Dec 15 | 0 | -5 | 6 | 0 |
Quality Earnings: ANNX is currently unprofitable.
Growing Profit Margin: ANNX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ANNX is unprofitable, and losses have increased over the past 5 years at a rate of 8.6% per year.
Accelerating Growth: Unable to compare ANNX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ANNX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (1.5%).
Return on Equity
High ROE: ANNX has a negative Return on Equity (-731.47%), as it is currently unprofitable.